Fredag 27 December | 18:55:50 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-01-29 08:30 Bokslutskommuniké 2024
2024-11-08 - Extra Bolagsstämma 2024
2024-10-29 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-28 - Årsstämma
2024-05-17 - X-dag ordinarie utdelning ZICC 0.00 SEK
2024-04-29 - Kvartalsrapport 2024-Q1
2024-01-26 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-06-21 - X-dag ordinarie utdelning ZICC 0.00 SEK
2023-06-20 - Årsstämma
2023-04-26 - Kvartalsrapport 2023-Q1
2023-01-27 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-04-29 - X-dag ordinarie utdelning ZICC 0.00 SEK
2022-04-28 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2022-01-18 - Extra Bolagsstämma 2022
2021-10-28 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-04-28 - X-dag ordinarie utdelning ZICC 0.00 SEK
2021-04-27 - Årsstämma
2021-04-23 - Kvartalsrapport 2021-Q1
2021-02-11 - Bokslutskommuniké 2020
2020-11-06 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-06-17 - X-dag ordinarie utdelning ZICC 0.00 SEK
2020-06-16 - Årsstämma
2020-04-17 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-05-20 - Årsstämma
2019-05-10 - X-dag ordinarie utdelning ZICC 0.00 SEK
2019-05-09 - Kvartalsrapport 2019-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst verksamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.
2024-04-26 15:10:00

In addition to its existing network of high expertise suppliers and consultants, Ziccum has signed a long-term agreement with the GMP equipment specialist RFR Solutions, for the next phase in the industrialization and scale-out of the LaminarPaceTM equipment.

The new product development and manufacturing partner RFR Solutions has excellent expertise in prototyping, optimizing design and industrialization of demanding high precision equipment for highly regulated industries. Based on good collaborative efforts with key design items for the LaminarPace equipment in recent months, Ziccum has signed a long-term agreement with this partner.

Ziccum’s parallel development projects for LaminarPaceTM – LaPaSim (an advanced 3D digital modeling project in partnership with the ICP Institute of Computational Physics at the Zurich University of Applied Science’s School of Engineering) and the LaminarPace Masterplan (Ziccum’s comprehensive internal project developing, refining and optimizing LaminarPaceTM capabilities) – both continue to progress, optimize and accelerate the performance and industrial applicability of the system. To ensure high quality, high precision equipment development and manufacturing for the LaminarPaceTM path towards industrialization is critical. Having contracted a highly competent and professional partner for manufacturing is complementing the Ziccum offering to the pharmaceutical industry, and is an important milestone.

CEO Ann Gidner: “we are very pleased to formalize this productive collaboration to ensure high class technology, materials and manufacturing expertise in order for us to deliver robust performance of the equipment with GMP compliance. Our partner is a true precision player, delivering their services for example to CERN in Switzerland. This will make an important contribution to the on-going scale out of LaminarPace and it will provide additional value in our industry dialogues”.